SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+11.87%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$807M
AUM Growth
+$807M
(+16%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
18.35%
Top 10 Holdings %
Top 10 Hldgs %
42.29%
Holding
104
New
31
Increased
25
Reduced
14
Closed
27
Top Buys
| 1 |
Smith & Nephew
SNN
|
$27.1M |
| 2 |
SI-BONE Inc
SIBN
|
$20.9M |
| 3 |
Rigel Pharmaceuticals
RIGL
|
$16.9M |
| 4 |
Natera
NTRA
|
$16.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$15.9M |
Top Sells
| 1 |
CVRx
CVRX
|
$18.6M |
| 2 |
Vericel Corp
VCEL
|
$17.1M |
| 3 |
Eli Lilly
LLY
|
$14.3M |
| 4 |
HCA Healthcare
HCA
|
$8.29M |
| 5 |
Krystal Biotech
KRYS
|
$8.25M |
Sector Composition
| 1 | Healthcare | 97.15% |
| 2 | Consumer Staples | 1.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Enanta Pharmaceuticals
ENTA
$189M
| $4.71M | 0.49% |
116,514
-21,300
| -15% | -$861K |
|
52
Mineralys Therapeutics
MLYS
$1.94B
| $4.28M | 0.44% |
+273,241
| New | +$4.28M |
|
|
PVLA
53
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $4.04M | 0.42% |
51,686
+39,186
| +313% | +$3.06M |
|
|
CERE
54
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $3.78M | 0.39% |
+155,000
| New | +$3.78M |
|
|
ABCM
55
DELISTED
Abcam plc American Depositary Shares
ABCM
| $3.77M | 0.39% |
+279,971
| New | +$3.77M |
|
56
Inspire Medical Systems
INSP
$2.53B
| $3.65M | 0.38% |
15,600
-30,600
| -66% | -$7.16M |
|
57
Acadia Pharmaceuticals
ACAD
$4.34B
| $3.58M | 0.37% |
+190,000
| New | +$3.58M |
|
58
Annexon
ANNX
$225M
| $3.52M | 0.37% |
+915,400
| New | +$3.52M |
|
|
FNA
59
DELISTED
Paragon 28, Inc.
FNA
| $3.48M | 0.36% |
+204,018
| New | +$3.48M |
|
60
Pharvaris
PHVS
$1.41B
| $2.71M | 0.28% |
336,900
+26,900
| +9% | +$217K |
|
61
FibroGen
FGEN
$48.4M
| $2.42M | 0.25% |
5,179
+640
| +14% | +$299K |
|
62
AngioDynamics
ANGO
$432M
| $2.33M | 0.24% |
+225,000
| New | +$2.33M |
|
63
Aclaris Therapeutics
ACRS
$223M
| $2.01M | 0.21% |
+249,000
| New | +$2.01M |
|
|
CSII
64
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.89M | 0.2% |
+95,346
| New | +$1.89M |
|
65
Amylyx Pharmaceuticals
AMLX
$877M
| $1.85M | 0.19% |
63,214
+12,578
| +25% | +$369K |
|
|
PRDS
66
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $1.65M | 0.17% |
1,250,000
| – | – |
|
67
Transmedics
TMDX
$3.65B
| $1.44M | 0.15% |
19,000
-24,500
| -56% | -$1.86M |
|
68
RxSight
RXST
$364M
| $1.33M | 0.14% |
+80,000
| New | +$1.33M |
|
69
Axsome Therapeutics
AXSM
$6.09B
| $1.28M | 0.13% |
20,700
-29,300
| -59% | -$1.81M |
|
70
Lyra Therapeutics
LYRA
$11.8M
| $1.19M | 0.12% |
11,848
| – | – |
|
71
Orchestra BioMed
OBIO
$147M
| $1.18M | 0.12% |
+60,450
| New | +$1.18M |
|
72
Pulmonx
LUNG
$67.6M
| $794K | 0.08% |
71,000
| – | – |
|
73
Xilio Therapeutics
XLO
$37.5M
| $719K | 0.07% |
226,941
| – | – |
|
74
Immunic
IMUX
$79.4M
| $447K | 0.05% |
+300,000
| New | +$447K |
|
75
Y-mAbs Therapeutics
YMAB
$390M
| $437K | 0.05% |
87,182
| – | – |
|